Document:

EXHIBIT 10.1

 

EMPLOYMENT AGREEMENT

 

This EMPLOYMENT AGREEMENT (“Agreement”)
is made as of the 8th day of August 2022, to be effective as of the Commencement Date (as defined below), between Biostage,
Inc., a Delaware corporation (the “Company”), and Joseph Damasio (“Executive”). For purposes of this Agreement
the “Company” shall refer to the Company and any of its predecessors.

 

WHEREAS, the Company desires to employ
Executive and Executive desires to be employed by the Company on the terms contained herein.

 

NOW, THEREFORE, in consideration of the
mutual covenants and agreements herein contained and other good and valuable consideration, the receipt and sufficiency of which is hereby
acknowledged, the parties agree as follows:

 

1. Employment. The term of this
Agreement shall extend from August 8, 2022 (the “Commencement Date”) until terminated by the Company or the Executive in accordance
herewith. The term of this Agreement shall be subject to termination as provided in Paragraph 6 and may be referred to herein as
the “Period of Employment.”

 

2. Position and Duties. During
the Period of Employment, Executive shall serve as the Chief Financial Officer of the Company and shall report to the Chief Executive
Officer (interim or otherwise) and have such powers and duties as may from time to time be prescribed by the Chief Executive Officer (interim
or otherwise) or Board of Directors (the “Board”) of the Company, provided that such duties are consistent with Executive’s
position or other positions that he may hold from time to time.  Executive shall devote his full working time and efforts to the
business and affairs of the Company. Notwithstanding the foregoing, Executive may: (a) serve on other boards of directors, with the approval
of the Board; (b) manage Executive’s personal investments on Executive’s own personal time, including, without limitation
the right to make passive investments in the securities of (i) any entity which Executive does not control, directly or indirectly, and
which does not compete with Company, or (ii) any publicly held entity, so long as Executive’s aggregate direct and indirect interest
does not exceed two percent (2%) of the issued and outstanding securities of any class of securities of such publicly held entity; and
(c) Executive’s participation in civic and charitable activities, including as a member of a board of a civic or charitable organization,
as long as in each case such management, ownership, or service does not materially interfere with Executive’s performance of his
duties to the Company as provided in this Agreement or otherwise breach any obligations of Executive to the Company.

 

3. Compensation and Related Matters.

 

(a) Base
Salary. Executive’s initial annual base salary shall be $20,833.33 per month, which annualizes to Two Hundred Fifty Thousand
Dollars ($250,000). Executive’s base salary shall be reviewed annually by the Board or a Committee thereof; provided, however that
the annual base salary shall not be lower than $250,000 without the Executive’s consent (except for across-the-board reductions
similarly affecting all or substantially all executive officers). Such base salary in effect at any given time is referred to herein as
“Base Salary.” The Base Salary shall be payable in substantially equal installments on a bi-weekly or more frequent basis,
subject to tax and other applicable withholdings.

 

(b) Options. Subject
to the terms and conditions of the Company’s Amended and Restated Equity Incentive Plan (as amended, the “Plan”), and
the Executive’s timely execution of a stock option agreement evidencing the option grant, the Company will grant the Executive as
of the Commencement Date an option to purchase 116,156 shares of Common Stock. Subject to continued
employment through the applicable vesting dates, the option shall vest in four substantially equal annual increments on
each anniversary of the grant date. The option shall be a non-qualified stock option, and such grant shall each be subject to the
Plan and this Agreement.

 

(c) 2022 Bonus. Subject
to satisfaction of certain milestones mutually agreed by the Company and Executive in connection with this Agreement, the Executive shall
also receive a bonus pertaining to the remainder of fiscal 2022 in the amount of $25,000, which subject to withholding and deductions
required by law, shall be paid by the Company in a lump sum in the initial fiscal quarter of 2023 on or before March 15, 2023.

 

    1

     

    

 

(d) Expenses. Executive
shall be entitled to receive prompt reimbursement for all reasonable expenses incurred by him in performing services hereunder during
the Period of Employment, in accordance with the policies and procedures then in effect and established by the Company for its senior
executive officers. All reimbursements provided under this Agreement shall be made or provided in accordance with the requirements of
Section 409A (“Section 409A”) of the Code and the rules and regulations thereunder, including, where applicable, the requirement
that (i) any reimbursement is for expenses incurred during Executive’s lifetime (or during a shorter period of time specified in
this Agreement); (ii) the amount of expenses eligible for reimbursement during a calendar year may not affect the expenses eligible for
reimbursement in any other calendar year; (iii) the reimbursement of an eligible expense shall be made no later than the last day of the
calendar year following the year in which the expense is incurred; and (iv) the right to reimbursement or in kind benefits is not subject
to liquidation or exchange for another benefit.

 

(e) Other Benefits. Executive
shall be eligible to participate in such other annual bonus and other incentive compensation plans as the Board or a Committee thereof
shall determine from time to time for key management or highly compensated employees of the Company. Notwithstanding anything herein to
the contrary, the Executive may decline coverage under any Employee Benefit Plan of the Company to which he might otherwise be entitled,
except as otherwise required by law.

 

(f) Vacations. Executive
shall be entitled to twenty (20) paid vacation days in each calendar year, which shall be accrued ratably during the calendar year. 
Unless otherwise expressly permitted by the Company, any unused vacation days at the end of the calendar year shall be forfeited. Executive
shall also be entitled to all paid holidays provided by the Company to its executives. Notwithstanding anything herein to the contrary,
Executive shall be paid any accrued and unused vacation upon his separation of service of employment with the Company, if and as protected
by applicable law.

 

(g) Directors
and Officers Insurance and Indemnification. The Company shall also carry reasonable and customary D&O liability insurance
coverage for the benefit of its officers and directors, including Executive, during the entire term of this Agreement and for a customary
tail period following the termination of Executive’s employment or service as a member of the Board. Executive shall be entitled
to be indemnified by the Company to the fullest extent permitted by the applicable state law and consistent with Company’s Amended
and Restated Certificate of Incorporation, and Amended and Restated By-laws, each as amended.

 

4. Unauthorized Disclosure. 

 

(a) Confidential Information.
Executive acknowledges that in the course of his employment with the Company (and, if applicable, its predecessors), he has been allowed
to become, and will continue to be allowed to become, acquainted with the Company’s business affairs, information, trade secrets,
and other matters which are of a proprietary or confidential nature, including but not limited to the Company’s and its affiliates’
and predecessors’ operations, business opportunities, price and cost information, finance, customer information, business plans,
various sales techniques, manuals, letters, notebooks, procedures, reports, products, processes, services, and other confidential information
and knowledge concerning the Company’s and its affiliates’ and predecessors’ business (collectively the “Confidential
Information”). The Company agrees to provide on an ongoing basis such Confidential Information as the Company deems necessary
or desirable to aid Executive in the performance of his duties. Executive understands and acknowledges that such Confidential Information
is confidential, and he agrees not to disclose such Confidential Information to anyone outside the Company except to the extent that (i) Executive
deems such disclosure or use reasonably necessary or appropriate in connection with performing his duties on behalf of the Company; (ii) Executive
is required by order of a court of competent jurisdiction (by subpoena or similar process) to disclose or discuss any Confidential Information,
provided that in such case, Executive shall inform the Company of such event within 24 hours of receiving notice of the court order, shall
cooperate with the Company in attempting to obtain a protective order or to otherwise restrict such disclosure, and shall only disclose
Confidential Information to the minimum extent necessary to comply with any such court order; (iii) such Confidential Information
becomes generally known to and available for use in any industry in which the Company does business (including without limitation the
regenerative medicine industry, the “Industry”), other than as a result of any action or inaction by Executive; or (iv) such
information has been rightfully received by a member of the Industry or has been published in a form generally available to the Industry
prior to the date Executive proposes to disclose or use such information. Executive further agrees that he will not during his employment
with the Company and/or at any time thereafter use such Confidential Information in competing, directly or indirectly, with the Company. At
such time as Executive shall cease to be employed by the Company, he will immediately turn over to the Company all Confidential Information,
including papers, documents, writings, electronically stored information, other property, and all copies of them provided to or created
by him during the course of his employment with the Company.

 

    2

     

    

 

(b) Heirs, successors, and legal representatives.
The foregoing provisions of this Paragraph 4 shall be binding upon Executive’s heirs, successors, and legal representatives. The
provisions of this Paragraph 4 shall survive the termination of this Agreement for any reason.

 

(c) Defend Trade Secrets Act Whistleblower Immunity. Executive acknowledges and understand that Executive shall not be held criminally
or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that (A) is made (i) in confidence
to a Federal, State, or local government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of
reporting or investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding,
if such filing is made under seal. Also, if Executive files a lawsuit for retaliation by an employer for reporting a suspected violation
of law, Executive may disclose the trade secret to Executive’s attorney and use the trade secret information in the court proceeding,
provided that Executive files any document containing the trade secret under seal and do not disclose the trade secret, except pursuant
to court order.

 

5. Covenant Not to Compete or Solicit
or Hire. In consideration for Executive’s employment by the Company under the terms provided in this Agreement and as a
means to aid in the performance and enforcement of the terms of the provisions of Paragraph 4, Executive agrees that

 

(a) during the
term of Executive’s employment with the Company and for a period of twelve (12) months thereafter (the “Non-Competition
Period”), Executive will not, directly or indirectly, as an owner, director, principal, agent, officer, employee, partner, consultant,
servant, or otherwise, carry on, operate, manage, control, or become involved in any manner with any business, operation, corporation,
partnership, association, agency, or other person or entity which is engaged in a business that produces or develops products that compete
or may compete directly with any of the Company’s products which are produced or being developed by the Company or any affiliate
of the Company during the last two years of your employment by the Company or which the Company or any affiliate of the Company has active
plans to produce or develop as of the date of Executive’s termination of employment with the Company during the last two years of
your employment by the Company, in any area or territory in which the Company or any affiliate of the Company conducts or has active plans
to conduct operations as of the date of the Executive’s termination of employment with the Company; provided, however, that the
foregoing shall not prohibit Executive from owning up to one percent (1%) of the outstanding stock of a publicly held company engaged
in the Industry. This Section 5(a) shall not apply to you in the event Executive’s employment is terminated by the Company without
Cause. In consideration of your agreement not to compete during the Non-Competition Period, the Company shall pay you an amount equal
to fifty percent (50%) of your highest annualized base salary in the two years immediately preceding the commencement of the Non-Competition
Period, to be paid in accordance with the Company’s normal payroll practices. For the purposes of this subsection 5(a), “highest
annualized base salary” shall mean the highest averaged amount of compensation paid to Executive for any twelve month period during
the two year period immediately preceding commencement of the Non-Competition Period, but shall not include any other form of compensation,
including but not limited to, commissions, bonuses, reimbursement of expenses, travel discounts or other fringe benefits; and

 

(b) during the
term of Executive’s employment with the Company and for a period of twelve (12) months thereafter, regardless of the reason
for termination of employment, Executive will not directly or indirectly solicit or induce any employee of the Company or any affiliate
of the Company to accept employment with Executive or with any business, operation, corporation, partnership, association, agency, or
other person or entity with which Executive may be associated, and Executive will not hire or employ or cause any business, operation,
corporation, partnership, association, agency, or other person or entity with which Executive may be associated to hire or employ any
employee of the Company.

 

Should Executive violate any of the provisions
of this Paragraph, then in addition to all other rights and remedies available to the Company at law or in equity, the duration of this
covenant shall automatically be extended for the period of time from which Executive began such violation until he permanently ceases
such violation. Executive acknowledges and agrees that the terms and conditions of this Paragraph 5 are reasonable with respect to its
duration, geographic area and scope.

 

    3

     

    

 

Executive acknowledges that full compliance with
the terms of this Agreement is necessary to protect the significant value of the Confidential Information and the customer and business
goodwill of the Company. Executive acknowledges that if he breaches this Agreement, the Company will be irreparably harmed and money damages
will not be an adequate remedy. As a result, Executive agrees that, in the event Executive breaches or threatens to breach any of the
terms or provisions of this Agreement, the Company shall be entitled to a preliminary or permanent injunction, without posting a bond
or other security, in order to prevent the continuation of such harm. Executive acknowledges that nothing in this Agreement will prohibit
the Company from also pursuing any other remedy and all remedies are cumulative. Executive agrees that the one-year restrictive period
under Sections 5(a) and (b) shall be respectively tolled for the same period in the event that Executive engages in the prohibited conduct
prior to the Company’s discovery of such violation. If Executive breaches his fiduciary duty to the Company or unlawfully takes,
physically, or electronically, property belonging to the Company, the one year restrictive period set forth in Sections 5(a) and (b) shall
be extended to twenty-four (24) months.

 

6.  Termination.  Executive’s
employment hereunder may be terminated without any breach of this Agreement under the following circumstances:

 

(a) Death. Executive’s
employment hereunder shall terminate upon his death.

 

(b) Disability. If, as a result
of Executive’s incapacity due to physical or mental illness, Executive shall have been absent from his duties hereunder on a full-time
basis for one hundred eighty (180) calendar days in the aggregate in any twelve (12) month period, the Company may terminate
Executive’s employment hereunder.

 

(c) Termination by Company For Cause.
At any time during the Period of Employment, the Company may terminate Executive’s employment hereunder for Cause if such termination
is approved by not less than a majority of the Board at a meeting of the Board called and held for such purpose. For purposes of
this Agreement, “Cause” shall mean: (A) conduct by Executive constituting an act of willful misconduct in connection
with the performance of his duties, including, without limitation, misappropriation of funds or property of the Company or any of its
affiliates; (B) criminal or civil conviction of Executive, a plea of nolo contendere by Executive or conduct by Executive that would
reasonably be expected to result in injury to the reputation of the Company if he were retained in his position with the Company, including,
without limitation, conviction of a felony involving moral turpitude; (C) continued, willful and deliberate non-performance by Executive
of his duties hereunder (other than by reason of Executive’s physical or mental illness, incapacity or disability); (D) a breach
by Executive of any of the provisions contained in Sections 4 and 5 of this Agreement; or (E) a violation by Executive of the Company’s
material employment policies which has continued following written notice of such violation from the Board. If the Company determines
that any alleged Cause under Sections 6(c)(A), (D), and (E) is reasonably susceptible to being cured, the Company shall provide Executive
with written notice specifying the basis for the alleged Cause and Executive shall have thirty (30) days to cure such Cause.

 

(d) Termination Without Cause.
At any time during the Period of Employment, the Company may terminate Executive’s employment hereunder without Cause if such termination
is approved by a majority of the Board at a meeting of the Board called and held for such purpose. Any termination by the Company
of Executive’s employment under this Agreement which does not constitute a termination for Cause under Section 6(c) or result from
the death or disability of the Executive under Sections 6(a) or (b) shall be deemed a termination without Cause. 

 

    4

     

    

 

(e) Termination by Executive.
At any time during the Period of Employment, Executive may terminate his employment hereunder for any reason, including but not limited
to Good Reason.  For purposes of this Agreement, “Good Reason” shall mean that Executive has complied with the “Good
Reason Process” (hereinafter defined) following the occurrence of any of the following events: (A) a substantial diminution
or other substantial adverse change, not consented to by Executive (or caused by his disability as elsewhere provided herein), in the
nature or scope of Executive’s responsibilities, authorities, powers, functions, duties or reporting relationship; (B)  an
involuntary reduction in Executive’s Base Salary except for across-the-board reductions similarly affecting all or substantially
all executive officers; (C) a breach by the Company of any of its other material obligations under this Agreement and the failure
of the Company to cure such breach within thirty (30) days after written notice thereof by Executive; (D) the involuntary relocation
of the Company’s offices at which Executive is principally employed on the Commencement Date or the involuntary relocation of the
offices of Executive’s primary workgroup to a location more than 30 miles from such offices, or the requirement by the Company that
Executive be based anywhere other than the Executive’s principal work location on the Commencement Date on an extended basis, except
for required travel on the Company’s business; or (E) the failure of the Company to obtain the agreement from any successor
to the Company to assume and agree to perform this Agreement as required by Section 9 (each of which is hereinafter referred to as a “Good
Reason event”). “Good Reason Process” shall mean that (i) Executive reasonably determines in good faith that
a “Good Reason” event has occurred; (ii) Executive notifies the Company in writing of the occurrence of the Good Reason
event by no later than sixty (60) days after the initial occurrence of the event or condition constituting Good Reason; (iii) Executive
cooperates in good faith with the Company’s efforts, for a period not less than ninety (90) days following such notice, to
modify Executive’s employment situation; and (iv) notwithstanding such efforts, one or more of the Good Reason events continues
to exist and has not been modified in a manner acceptable to Executive. If the Company cures the Good Reason event during the ninety
(90) day period, Good Reason shall be deemed not to have occurred.

 

(f)       Notice
of Termination. Except for termination as specified in Section 6(a), any termination of Executive’s employment by the Company
or any such termination by Executive shall be communicated by written notice of termination (“Notice of Termination”) to the
other party hereto and shall be effective on the Date of Termination (as defined below).

 

(g)       Date
of Termination. “Date of Termination” shall mean: (A) if Executive’s employment is terminated by his
death, the date of his death; (B) if Executive’s employment is terminated on account of disability under Section 6(b) or by
the Company for Cause under Section 6(c) or without Cause under Section 6(d), the date on which Notice of Termination is given or such
later date as the Company may specify in the Notice of Termination; and (D) if Executive’s employment is terminated by Executive
under Section 6(e), thirty (30) days after the date on which a Notice of Termination is given or, if such termination is without
Good Reason, such later date up to sixty (60) days after the date on which such Notice of Termination is given as Executive may specify
in the Notice of Termination.

 

(h)       Separation
from Service. Notwithstanding anything herein to the contrary, to the extent necessary to comply with Section 409A of the Code, no
event shall constitute a “termination of employment” in this Agreement, unless such event is also a “separation from
service,” as that term is defined for purposes of Section 409A and Treasury Regulation §1.409A-3(a)(1).

 

(i)       Resignation.
Upon termination of the Executive’s employment hereunder for any reason, the Executive shall be deemed to have resigned from all
positions that the Executive holds as an officer of the Company or any of its subsidiaries and a director of any of such subsidiaries
(but for the avoidance of any doubt, not as a director of the Company), and the Executive will execute any resignation that may be requested
by the Company supplement this Agreement as evidence of such resignation. For the avoidance of any doubt, in the event of termination
of Executive’s employment for any reason other than death or disability, Executive shall remain a director of the Company following
such termination.

 

7. Compensation Upon Termination or
During Disability. 

 

(a) Death. If Executive’s
employment terminates by reason of his death, the Company shall, within sixty (60) days of death, pay in a lump sum to such person
as Executive shall designate in a notice filed with the Company or, if no such person is designated, to Executive’s estate, Executive’s
(a) accrued and unpaid Base Salary to the Date of Termination, (b) to the extent required by law, any other compensation actually earned
for periods ended prior to the date of Executive’s death (or other termination event), (c) to the extent required by law, accrued
and unused vacation, and (d) the amount of any expenses properly incurred by Executive on behalf of Company prior to any such termination
and has not yet been reimbursed (collectively, the “Accrued Obligations”). In addition to the foregoing, any payments to which
Executive’s spouse, beneficiaries, or estate may be entitled under any employee benefit plan shall also be paid in accordance with
the terms of such plan or arrangement. The payments made under this section shall fully discharge the Company’s obligations
hereunder.

 

    5

     

    

 

(b) Disability. During any
period that Executive fails to perform his duties hereunder as a result of incapacity due to physical or mental illness, Executive shall
continue to receive his Base Salary, until Executive’s employment is terminated due to disability in accordance with Section 6(b)
or until Executive terminates his employment in accordance with Section 6(e), whichever first occurs.  If there is a dispute about
whether Executive is disabled, the parties shall use the procedure described in Section 13, below, to resolve such dispute. If Executive’s
employment is terminated due to disability in accordance with Section 7(b), then the Company shall pay Executive all Accrued Obligations
through the Date of Termination in a lump-sum payment by no later than sixty (60) days after the Date of Termination. Upon termination
due to death prior to the termination first to occur as specified in the preceding sentence, Section 7(a) shall apply.

 

(c) Resignation other than for Good
Reason. If Executive voluntarily resigns from employment other than for Good Reason as provided in Section 6(e), then the Company
shall pay Executive all Accrued Obligations through the Date of Termination in a lump-sum payment by no later than sixty (60) days after
the Date of Termination. Thereafter, the Company shall have no further obligations to Executive except as otherwise expressly provided
under this Agreement, provided any such termination shall not adversely affect or alter Executive’s rights under any employee benefit
plan of the Company in which Executive, at the Date of Termination, has a vested interest, unless otherwise provided in such employee
benefit plan or any agreement or other instrument attendant thereto.

 

(d) Termination by Executive for Good
Reason or by the Company without Cause. Subject to the terms of Paragraph 16(a), and subject to the terms of this section, if
the Executive’s employment is terminated for Good Reason as provided in Section 6(e) or without Cause as provided in Section 6(d),
then the Company shall pay Executive all Accrued Obligations through the Date of Termination in a lump-sum payment by no later than sixty
(60) days after the Date of Termination. In addition, subject to the Executive’s execution of a general release of claims in
the form attached hereto as Exhibit A within 21 days after the Date of Termination and the expiration of the seven-day revocation
period applicable thereto without the Executive revoking his acceptance of such general release, commencing on the last day of the period
for signing and revoking the general release of claims generally in the form set forth in Exhibit A hereof (“Release”):

 

(i) the Company shall pay Executive
an amount equal to three (3) months of the Executive’s Base Salary rate at the Date of Termination (the “Severance Amount”).
The Severance Amount shall be paid in cash in equal installments over the period of three months from the date of commencement in accordance
with the Company’s standard payroll procedures.  Notwithstanding the foregoing, if the Executive breaches any of the provisions
contained in Paragraphs 4 and 5 of this Agreement, all payments of the Severance Amount shall immediately cease and the entire Severance
Amount shall be forfeited and become repayable to the Company to the extent paid. Furthermore, in the event Executive terminates his employment
for Good Reason as provided in Section 6(e), he shall be entitled to the Severance Amount only if he provides the Notice of Termination
provided for in Section 6(f) within thirty (30) days after he has complied with the Good Reason Process; and

 

(ii) upon the Date of Termination,
each unvested stock-based grant and award held by Executive at the Date of Termination (including all stock options) that would vest within
the twelve (12) months following the Date of Termination shall accelerate and become fully vested or non-forfeitable.

 

(e) Termination for Cause.
If Executive’s employment is terminated by the Company for Cause as provided in Section 6(c), then the Company shall pay Executive
all Accrued Obligations through the Date of Termination in a lump-sum payment by no later than sixty (60) days after the Date of Termination. Thereafter,
the Company shall have no further obligations to Executive except as otherwise expressly provided under this Agreement, provided any such
termination shall not adversely affect or alter Executive’s rights under any employee benefit plan of the Company in which Executive,
at the Date of Termination, has a vested interest, unless otherwise provided in such employee benefit plan or any agreement or other instrument
attendant thereto.  In addition, all stock options held by Executive as of the Date of Termination shall immediately terminate and
be of no further force and effect, and all other stock-based grants and awards shall be canceled or terminated in accordance with their
terms.

 

Nothing contained in the foregoing Sections 7(a) through 7(e) shall
be construed so as to affect Executive’s rights or the Company’s obligations relating to agreements or benefits which are
unrelated to termination of employment.

 

    6

     

    

 

8. Notice. For purposes of
this Agreement, notices and all other communications provided for in the Agreement shall be in writing and shall be deemed to have been
duly given when delivered or mailed by United States certified mail, return receipt requested, postage prepaid, addressed as follows:

 

if to the Executive:

 

At his home address as shown

in the Company’s personnel records;

 

if to the Company:

 

Biostage, Inc.

84 October Hill Road, Suite 11

Holliston, Massachusetts 01746

Attention: Chief Executive Officer

 

with a copy to:

 

Chad J. Porter

Burns & Levinson LLP

125 High Street

Boston, MA 02110

 

or to such other address as either party may have furnished to the
other in writing in accordance herewith, except that notices of change of address shall be effective only upon receipt.

 

9. Successor to Company. The
Company shall require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially
all of the business or assets of the Company expressly to assume and agree to perform this Agreement to the same extent that the Company
would be required to perform it if no succession had taken place. Failure of the Company to obtain an assumption of this Agreement
at or prior to the effectiveness of any succession shall be a breach of this Agreement.

 

10. Miscellaneous. No provisions
of this Agreement may be modified, waived, or discharged unless such waiver, modification, or discharge is agreed to in writing and signed
by Executive and such officer of the Company as may be specifically designated by the Board. No waiver by either party hereto of,
or compliance with, any condition or provision of this Agreement to be performed by such other party shall be deemed a waiver of similar
or dissimilar provisions or conditions at the same or at any prior or subsequent time. No agreements or representations, oral or
otherwise, express or implied, unless specifically referred to herein, with respect to the subject matter hereof have been made by either
party which are not set forth expressly in this Agreement. The validity, interpretation, construction, and performance of this Agreement
shall be governed by the laws of the Commonwealth of Massachusetts (without regard to principles of conflicts of laws).

 

11. Validity. The invalidity
or unenforceability of any provision or provisions of this Agreement shall not affect the validity or enforceability of any other provision
of this Agreement, which shall remain in full force and effect. The invalid portion of this Agreement, if any, shall be modified by any
court having jurisdiction to the extent necessary to render such portion enforceable.

 

12. Counterparts. This Agreement
may be executed in several counterparts, each of which shall be deemed to be an original but all of which together will constitute one
and the same instrument.

 

13. Arbitration; Other Disputes.
In the event of any dispute or controversy arising under or in connection with this Agreement, the parties shall first promptly try in
good faith to settle such dispute or controversy by mediation under the applicable rules of the American Arbitration Association before
resorting to arbitration. In the event such dispute or controversy remains unresolved in whole or in part for a period of thirty
(30) days after it arises, the parties will settle any remaining dispute or controversy exclusively by final, binding, and confidential
arbitration in Boston, Massachusetts, in accordance with the rules of the American Arbitration Association then in effect. Judgment
may be entered on the arbitrator’s award in any court having jurisdiction. Notwithstanding the above, the Company shall be
entitled to seek a restraining order or injunction or other equitable relief without the need to post a bond or provide other security
in the Superior Court or business litigation session located in Suffolk County or at the option of the Company, in the county where the
Executive resides to prevent any continuation of any violation of Paragraph 4, 5, 21, 22 or 23 any court of competent jurisdiction to
prevent any continuation of any violation of Paragraph 4 or 5 hereof. 

 

    7

     

    

 

14. Third-Party Agreements and Rights. Executive
represents to the Company that Executive’s execution of this Agreement, Executive’s employment with the Company and the performance
of Executive’s proposed duties for the Company will not violate any obligations Executive may have to any employer or other party,
and Executive will not bring to the premises of the Company any copies or other tangible embodiments of confidential information belonging
to or obtained from any such previous employment or other party.

 

15. Litigation and Regulatory Cooperation.
During and after Executive’s employment, Executive shall reasonably cooperate with the Company in the defense or prosecution of
any claims or actions now in existence or which may be brought in the future against or on behalf of the Company which relate to events
or occurrences that transpired while Executive was employed by the Company so long as such cooperation shall not materially and adversely
affect Executive or expose Executive to civil or criminal litigation. Executive’s cooperation in connection with such claims
or actions shall include, but not be limited to, being reasonably available to meet with counsel to prepare for discovery or trial and
to act as a witness on behalf of the Company at mutually convenient times. During and after Executive’s employment, Executive
also shall cooperate fully with the Company in connection with any investigation or review of any federal, state or local regulatory authority
as any such investigation or review relates to events or occurrences that transpired while Executive was employed by the Company. The
Company shall also provide Executive with compensation on an hourly basis at a rate equivalent to the hourly rate of the Company’s
existing Chief Financial Officer at the time of such cooperation calculated using a forty (40) hour week over fifty-two (52)
weeks for requested litigation and regulatory cooperation that occurs after his termination of employment, and reimburse Executive for
all reasonable costs and expenses incurred in connection with his performance under this Paragraph 15, including, but not limited to,
reasonable attorneys’ fees and costs.

 

16. Section 409A of the Code.

 

(a) Anything in this Agreement to
the contrary notwithstanding, if at the time of the Executive’s separation from service within the meaning of Section 409A
of the Code, the Company determines that the Executive is a “specified employee” within the meaning of Section 409A(a)(2)(B)(i)
of the Code, then to the extent any payment or benefit that the Executive becomes entitled to under this Agreement on account of the Executive’s
separation from service would be considered deferred compensation subject to the 20 percent additional tax imposed pursuant to Section 409A(a)
of the Code as a result of the application of Section 409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit
shall not be provided until the date that is the earlier of (A) six months and one day after the Executive’s separation from
service, or (B) the Executive’s death. Each payment of severance pay or other compensation under this Agreement is a separate
payment for purposes of section 409A of the Code. To the extent necessary to comply with Section 409A, if the period for considering and
executing the Release under this Agreement spans or could span two calendar years, then the severance or payment will not be made or commence
until the later calendar year.

 

(b) The parties intend that any deferred
compensation payable under this Agreement will be administered in accordance with Section 409A of the Code. To the extent that any
provision of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such
a manner so that all payments hereunder comply with Section 409A of the Code. The parties agree that this Agreement may be amended,
as reasonably requested by either party, and as may be necessary to fully comply with Section 409A of the Code and all related rules
and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party.

 

(c) The Company makes no representation
or warranty and shall have no liability to the Executive or any other person if any provisions of this Agreement are determined to constitute
deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, such Section.
The parties agree to reasonably cooperate and work together to adopt amendments to this Agreement to the extent necessary to comply with
Section 409A of the Code with the intent to place Executive in the same or a substantially equivalent economic position.

 

(d) Notwithstanding anything herein
to the contrary, if Section 409A of the Code is applicable to any deferred compensation hereunder, no event shall constitute a “termination
of employment” in this Agreement, unless such event is also a “separation from service,” as that term is defined for
purposes of Section 409A of the Code, and Treasury Regulation §1.409A-3(a)(1) and §1.409A-1(h).

 

    8

     

    

 

17. Recoupment. Notwithstanding
anything herein to the contrary, Executive may be required to forfeit or repay any or all compensation received by Executive under this
Agreement pursuant to the terms of any compensation recovery, recoupment or claw-back policy that may be adopted by or applicable to Company
executives with respect to or under the Dodd-Frank Wall Street Reform and Consumer Protection Act.

18. Survival. Notwithstanding anything
to the contrary in this Agreement, the provisions of Sections 4, 5, 7, 8, 20, 21, 22 and 23 of this Agreement, and any other Sections
of this Agreement that must survive the termination of employment or expiration of the Agreement in order to effectuate the intent of
the parties, shall survive termination of Executive’s employment or expiration of the Agreement.

 

19. Review. Executive understands
that he has the right to consult with counsel prior to signing this Agreement and has either availed himself of that right or knowingly,
willfully and freely decided not to do so. Executive acknowledges that this Agreement was provided to Executive before or with the formal
offer of employment.

 

20. Binding Nature of Agreement.
This Agreement shall be binding upon the Executive and upon his heirs, administrators, representatives, executors, successors and assigns,
and shall inure to the benefit of the Executive and the Company and to their heirs, administrators, representatives, executors, successors,
and assigns.

 

21. Ownership of Inventions and Works of
Authorship. Executive acknowledges that all ideas, developments, processes, discoveries, inventions, improvements, suggestions,
derivations, modifications, methods, programs, concepts, works, reports, procedures, data, documentation, writings, and applications,
whether they are patentable or not, which are made, devised, conceived, reduced to practice, developed or perfected by Executive alone
or with any other person or persons during the term of Executive’s employment by the Company which relate to or arise out of the
actual and/or anticipated business activities of the Company and which were created using any Company resources of any kind, including
other employees or by virtue of having access to and/or using Confidential Information (“Inventions”) will be the sole and
exclusive property of the Company. Executive further acknowledges that all Inventions and original works of authorship which are made
by Executive (solely or jointly with others) within the scope of and during the period of his or her employment with the Company and which
are protectable by copyright are “works made for hire,” as that term is defined in the United States Copyright Act (“Works”)
and are solely and exclusively owned by the Company. Executive agrees to disclose to the Company promptly and fully all Inventions and
Works. For all Inventions, and to the extent that any Works are not “works made for hire,” Executive hereby assigns and agrees
to assign to the Company all Executive’s right, title and interest in and to all Inventions and such Works and all associated goodwill.
Executive understands and agrees that the decision whether or not to commercialize or market any Invention is within the Company’s
sole discretion and for the Company’s sole benefit, and that no royalty will be due to Executive as a result of the Company’s
efforts to commercialize or market any such invention. Executive agrees to cooperate with and assist the Company, or its designee, in
every proper way to secure the Company’s rights in the Inventions and any copyrights, patents, mask work rights or other intellectual
property rights relating thereto in any and all countries which the Company shall deem necessary in order to apply for and obtain such
rights and in order to assign and convey to the Company, its successors, assigns, and nominees the sole and exclusive rights, title and
interest in and to such Inventions and related goodwill, and any copyrights, patents, mask work rights or other intellectual property
rights relating thereto. Executive agrees that Executive’s obligation to execute or cause to be executed, when it is in Executive’s
power to do so, any such instrument or papers shall continue after the termination of this Agreement. If the Company is unable because
of Executive’s mental or physical incapacity or for any other reason to secure Executive’s signature to apply for or to pursue
any application for any United States or foreign patents or copyright registrations covering Inventions or original works of authorship
assigned to the Company as above, then Executive hereby irrevocably designates and appoints the Company’s duly authorized officers
as Executive’s agent and attorney in fact, to act for and on Executive’s behalf and stead to execute and file any such applications
and to do all other lawfully permitted acts to further the prosecution and issuance of letters patent or copyright registrations thereon
with the same legal force and effect as if executed by Executive. Notwithstanding the foregoing, any provision in this Agreement requiring
Executive to assign or license, or to offer to assign or license, Executive’s rights in any Development to the Company does not
apply to an invention or work of authorship that Executive developed entirely on Executive’s own time without using or referring
to the Company’s resources, equipment, supplies, facilities, or Confidential Information, except for those inventions or works of
authorship that either: (a) at the time of creation, conception or reduction to practice of the work or invention relate to the Company’s
business, or to actual or demonstrably anticipated research or development of the Company, or (b) result from any work performed by Executive
for the Company; in which cases such provisions do apply. Executive acknowledges that Executive bears the burden of proving that an invention
or work of authorship is so exempt from the assignment provisions of this Agreement. Executive agrees to promptly disclose to the Company,
in confidence, all inventions or works of authorship made solely by Executive or jointly with others at any time during the term of Executive’s
employment with the Company, for a review process under which the Company may determine such issues as may arise, including the Company’s
rights and Executive’s rights in such inventions or works of authorship. For the avoidance of any doubt, the Executive’s intellectual
property rights pertaining to his Zero Carbon business are not Inventions or Works hereunder.

 

    9

     

    

 

22. Third-Party Agreements and Rights.
The Executive hereby confirms, that the Executive is not bound by the terms of any agreement with any previous employer or other party
which restricts in any way the Executive's use or disclosure of information or the Executive's engagement in any business. The Executive
represents to the Company that the Executive's execution of this Agreement, the Executive's employment with the Company and the performance
of the Executive's proposed duties for the Company will not violate any obligations the Executive may have to any such previous employer
or other party. In the Executive's work for the; Company, the Executive will not disclose or make use of any information in violation
of any agreements with or rights of any such previous employer or other party, and the Executive will not bring to the premises of the
Company any copies or other tangible embodiments of non-public information belonging to or obtained from any such previous employment
or third party.

 

23. Return of Company Property.
Upon termination of Executive’s employment with the Company or upon earlier demand by the Company, Executive agrees to immediately
return all Company property, including, but not limited to, any computer equipment, mobile phones, smartphones, iPhones, iPads and similar
electronic devices, office keys, credit and telephone cards, ID and access cards, and all original and duplicate copies of your work product
and of files, calendars, books, records, notes, notebooks, manuals, computer disks, diskettes, external drives, thumb drives, memory cards
and sticks, and any other digital, magnetic and other media materials Executive has in his or her possession or control belonging to the
Company, or containing Confidential Information.

 

[signatures on following page]

 

    10

     

    

 

IN WITNESS WHEREOF, the parties have executed
this Agreement effective on the date and year first above written.

 

	 	 	 	 
	 	BIOSTAGE, INC.
	 	 	 
	 	By:	/s/ David Green
	 	 	Name:	David Green
	 	 	Title:	Interim Chief Executive Officer
	 	 
	 	EXECUTIVE
	 	 	 
	 	 	/s/ Joseph Damasio
	 	 	Joseph Damasio

 

     

     

    

 

EXHIBIT A- FORM OF GENERAL RELEASE OF CLAIMS

 

This Release Agreement (the “Release Agreement”)
is entered into by _______________________ (the “Executive”) in favor of Biostage, Inc. (the “Company”).
This is the Release Agreement referenced in the Employment Agreement between the Executive and the Company dated __________________________
(as amended, the “Employment Agreement”). The consideration for the Executive’s agreement to this Release Agreement
consists of certain termination benefits as set forth in the Employment Agreement and the terms of this Release Agreement.

 

The Executive agrees as follows:

 

1.      Release.
The Executive voluntarily releases and forever discharges the Company and each of its subsidiaries, affiliates, predecessors, successors,
assigns, and current and former directors, officers, employees, representatives, attorneys, and agents (any and all of whom or which
are hereinafter referred to as “Company Parties”), from any and all charges, complaints, claims, liabilities, obligations,
promises, agreements, controversies, damages, actions, causes of action, suits, rights, demands, costs, losses, debts and expenses (including
attorney’s fees and costs actually incurred), of any nature whatsoever, known or unknown (collectively, “Claims”)
that the Executive now has, owns or holds, or claims to have, own, or hold, or that he at any time had, owned, or held, or claimed to
have had, owned, or held against any Company Party or Parties. This general release of Claims includes, without implication of limitation,
the release of all Claims:

 

 

	•	 	relating to the Executive’s employment by and termination from employment with the Company; 

 

	•	 	of wrongful discharge; 

 

	•	 	of breach of contract; 

 

	•	 	
    of retaliation or discrimination under federal, state or
    local law (including, without limitation, Claims of age discrimination or retaliation under the Age Discrimination in Employment Act,
    Claims of disability discrimination or retaliation under the Americans with Disabilities Act, Claims of discrimination or retaliation
    under Title VII of the Civil Rights Act of 1964 and Claims of discrimination or retaliation under Mass. Gen. Laws ch. 151B);

     

	•	 	under the Massachusetts Weekly Payment of Wages Act, the Massachusetts Fair Employment Practice Act, and the Fair Labor Standards Act,

 

	•	 	under any other federal or state statute, to the fullest extent that Claims may be released; 

 

	•	 	of defamation or other torts; 

 

	•	 	of violation of public policy; 

 

	•	 	for salary, bonuses, vacation pay or any other compensation or benefits; and 

 

	•	 	for damages or other remedies of any sort, including, without limitation, compensatory damages, punitive damages, injunctive relief and attorney’s fees. 

2.         Limitations on Release.

 

(a) Employment Agreement. Nothing in this
Release Agreement limits the Executive’s or the Company’s rights under the Employment Agreement.

 

     

     

    

 

(b) Benefit and Enforcement Rights. Nothing
in this Release Agreement is intended to release or waive the Executive’s right to COBRA, unemployment insurance benefits or any
accrued and vested retirement benefits, the right to seek enforcement of this Release Agreement or any rights referenced in this Section
of this Release Agreement.

 

(c) Indemnification. It is further understood
and agreed that the Executive’s rights to indemnification as provided in the Company’s certificate of incorporation, bylaws,
each as amended, or any indemnification agreement between the Company and the Executive (it being acknowledged and agreed by the Executive
that, as of the date of this Agreement, there are no amounts owing to the Executive pursuant to any such indemnification rights), remain
fully binding and in full effect subsequent to the execution of this Release Agreement.

 

(d) Exceptions. This Release Agreement
does not prohibit or restrict the Executive from communicating, providing relevant information to or otherwise cooperating with the EEOC
or any other governmental authority with responsibility for the administration of fair employment practices laws regarding a possible
violation of such laws or responding to any inquiry from such authority, including an inquiry about the existence of this Release Agreement
or its underlying facts; provided that such interaction with EEOC or any other governmental authority shall not result in the Executive’s
receipt of any monetary benefit or substantial equivalent thereof. This Release Agreement also does not preclude the Executive from benefiting
from classwide injunctive relief awarded in any fair employment practices case brought by any governmental agency; provided that such
relief does not result in the Executive’s receipt of any monetary benefit or substantial equivalent thereof.

 

3.        No
Assignment. The Executive represents that he has not assigned to any other person or entity any Claims against any Company Party.

 

4.        No
Disparagement. The Executive shall not make any disparaging statements about the Company, members of the Board of Directors, any officer
of the Company or any other employee of the Company, and the Company (acting through its officers and directors) shall not make any disparaging
statements about Executive. The Executive shall direct his immediate family not to make any disparaging statements about any of the foregoing.
Any statement by a member of his immediate family shall be deemed to be a statement by the Executive for purposes of this paragraph. The
Executive shall be considered to represent that he has complied and shall continue to comply with the non-disparagement obligations under
this paragraph from the Date of Termination (as defined in the Employment Agreement); provided that this representation shall have
no effect if this Release Agreement does not become effective. Notwithstanding the foregoing, nothing in this paragraph shall be construed
to apply to any statements made in the course of testimony in a legal proceeding or in any required written statements in any such proceeding.

 

5.        Litigation and Regulatory Cooperation.
The Executive shall reasonably cooperate with the Company in the defense or prosecution of any claims or actions now in existence or which
may be brought in the future against or on behalf of the Company which relate to events or occurrences that transpired while Executive
was employed by the Company; provided, however, that such cooperation shall not materially and adversely affect Executive or expose Executive
to an increased probability of civil or criminal litigation. Executive’s cooperation in connection with such claims or actions shall
include, but not be limited to, being available to meet with counsel to prepare for discovery or trial and to act as a witness on behalf
of the Company at mutually convenient times. Executive also shall cooperate fully with the Company in connection with any investigation
or review of any federal, state or local regulatory authority as any such investigation or review relates to events or occurrences that
transpired while Executive was employed by the Company. The Company shall also provide Executive with compensation on an hourly basis
at a rate equivalent to the hourly rate of the Executive’s last annual Base Salary (as defined in the Employment Agreement) calculated
using a forty (40) hour week over fifty-two (52) weeks for requested litigation and regulatory cooperation that occurs after
his termination of employment, and reimburse Executive for all costs and expenses incurred in connection with his performance under this
Section 5, including, but not limited to, reasonable attorneys’ fees and costs.

 

     

     

    

 

6.        Reaffirmation of Post-Employment Restrictive
Covenants. The Executive reaffirms the restrictive covenants under the Employment Agreement to which he is subject, including without
limitation, the covenants restricting the disclosure and use of confidential information set forth in Section 4 of the Employment Agreement
and covenants regarding non-competition, non-solicitation and non-hiring set forth in Section 5 of the Employment Agreement.

 

7.        Right to Consider and Revoke Release Agreement.
This Release Agreement shall be considered to have been offered to the Executive on the Termination Date as defined in the Employment
Agreement. The Executive acknowledges that he has been given the opportunity to consider this Release Agreement for a period ending twenty-one
(21) days after the Termination Date. In the event that the Executive has executed this Release Agreement within less than twenty-one
(21) days of the Termination Date, the Executive acknowledges that such decision was entirely voluntary and that he had the opportunity
to consider this Release Agreement until the end of the twenty-one (21) day period. To accept this Release Agreement, the Executive
shall deliver a signed Release Agreement to the Company’s Board of Directors within such twenty-one (21) day period. The Executive
acknowledges that for a period of seven (7) days from the date when the Executive executes this Release Agreement (the “Revocation Period”),
he shall retain the right to revoke this Release Agreement by written notice that is received by the Board of Directors of the Company
before the end of the Revocation Period. This Release Agreement shall take effect only if it is executed by the Executive within the twenty-one
(21) day period as set forth above and if it is not revoked pursuant to the preceding sentence. If those conditions are satisfied,
this Release Agreement shall become effective and enforceable on the date immediately following the last day of the Revocation Period
(the “Effective Date”).

 

8.        Consideration Owed. Executive affirms
and agrees that as of the date of this Release Agreement, you acknowledge that you will be or have been paid any and all wages (including
all base compensation and, if applicable, any and all overtime, commissions, and bonuses) to which you are or were entitled as of the
date of termination of employment, and that no other wages (including all base compensation and, if applicable, any and all incentive
compensation and bonuses) are due to Executive. Executive acknowledges that Executive is unaware of any facts or circumstances indicating
that Executive may have an outstanding claim for unpaid wages, improper deductions from pay, or any violation of the Massachusetts Weekly
Payment of Wages Act (M.G.L. c. 149, s. 148) or the Fair Labor Standards Act or any other federal, state or local laws, rules, ordinances
or regulations that are related to payment of wages.

 

9.        Other Terms.

 

(a) Legal Representation; Review of Release
Agreement. The Executive acknowledges that he has been advised to discuss all aspects of this Release Agreement with his attorney.
The Executive represents that he has carefully read and fully understands all of the provisions of this Release Agreement and that he
is voluntarily entering into this Release Agreement.

 

(b) Binding Nature of Release Agreement.
This Release Agreement shall be binding upon the Executive and upon his heirs, administrators, representatives, executors, successors
and assigns, and shall inure to the benefit of the Executive and the Company and to their heirs, administrators, representatives, executors,
successors, and assigns.

 

(c) Modification of Release Agreement; Waiver.
This Release Agreement may be amended, revoked, changed, or modified only upon a written agreement executed by both the Executive and
the Company. No modification waiver of any provision of this Release Agreement will be valid unless it is in writing and signed by the
party against whom such waiver is charged. The failure of the Company to require the performance of any term or obligation of this Release
Agreement, or the waiver by the Company of any breach of this Release Agreement, shall not prevent any subsequent enforcement of such
term or obligation or be deemed a waiver of any subsequent breach.

 

     

     

    

 

(d) Severability. In the event that at
any future time it is determined by a court of competent jurisdiction that any covenant, clause, provision or term of this Release Agreement
is illegal, invalid or unenforceable, the remaining provisions and terms of this Release Agreement shall not be affected thereby and the
illegal, invalid or unenforceable term or provision shall be severed from the remainder of this Release Agreement. In the event of such
severance, the remaining covenants shall be binding and enforceable.

 

(e) Enforcement. Sections 4, 5 and 6 of
this Release Agreement shall be subject to enforcement pursuant to the same procedures that apply to a breach of Sections 4 or 5 of the
Employment Agreement (as further detailed in Section 13 of the Employment Agreement). Any other disputes concerning this Release Agreement
shall be subject to resolution pursuant to Section 13 of the Employment Agreement.

 

(f) Governing Law and Interpretation.
This Release Agreement shall be deemed to be made and entered into in the Commonwealth of Massachusetts, and shall in all respects be
interpreted, enforced and governed under the laws of Massachusetts, without giving effect to the conflict of laws provisions of Massachusetts
law. The language of all parts of this Release Agreement shall in all cases be construed as a whole, according to its fair meaning, and
not strictly for or against the Executive or the Company.

 

(h) Entire Agreement; Absence of Reliance.
This Release Agreement constitutes the entire agreement of the Executive concerning any subject matter of this Release Agreement and supersedes
all prior agreements between the Executive and the Company with respect to any related subject matter, except the Employment Agreement.
The Executive acknowledges that he is not relying on any promises or representations by the Company or its agents, representatives or
attorneys regarding any subject matter addressed in this Release Agreement, other than the provision of the Employment Agreement pursuant
to which Executive is to receive certain consideration in return for signing this Release Agreement and allowing it to become effective.

 

So agreed by the Executive.

 

	 	 	 
	
 

	 	
 

	Executive   	 	 	DateExhibit 4.1 

 

THE REGISTERED HOLDER OF THIS PURCHASE WARRANT
BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE WARRANT OR CAUSE THIS PURCHASE
WARRANT TO BE SUBJECT TO ANY HEDGING, SHORT SALE, DERIVATIVE, PUT, OR CALL TRANSATION THAT WOULD RESULT IN THE EFFECTIVE ECONOMIC DISPOSITION
OF THE PURCHASE WARRANT OR THE SECURITIES UNDERLYING THE PURCHASE WARRANT FOR A PERIOD OF ONE HUNDRED EIGHTY (180) DAYS FROM THE COMMENCEMENT
OF SALES OF THIS OFFERING PURSUANT TO THE REGISTRATION STATEMENT OF THE COMPANY’S SECURITIES (FILE NO. 333-264575), EXCEPT THAT
SUCH LOCK-UP RESTRICTION DOES NOT PROHIBIT (I) TRANSFERS TO ANY UNDERWRITER OR SELECTED DEALER PARTICIPATING IN THE OFFERING AND ITS OFFICERS
OR PARTNERS, ITS REGISTERED PERSONS OR AFFILIATES, IF ALL TRANSFERRED SECURITIES REMAIN SUBJECT TO THE LOCK-UP RESTRICTION FOR THE REMAINDER
OF THE 180-DAY LOCK-UP PERIOD, (II) EXERCISE OR CONVERSION OF THE PURCHASE WARRANT, IF ALL SECURITIES RECEIVED REMAIN SUBJECT TO THE LOCK-UP
RESTRICTION FOR THE REMAINDER OF THE 180-DAY LOCK-UP PERIOD, OR (III) TRANSFER OR SALE OF THE PURCHASE WARRANT OR SECURITIES THEREUNDER
BACK TO THE COMPANY, IN A TRANSACTION EXEMPT FROM REGISTRATION WITH THE SECURITIES AND EXCHANGE COMMISSION, AS PROVIDED FOR IN FINRA RULE
5110(E)(2). 

 

THIS PURCHASE WARRANT IS NOT EXERCISABLE PRIOR
TO AUGUST 9, 2022. VOID AFTER 5:00 P.M., EASTERN TIME, AUGUST 8, 20271.

 

UNDERWRITER’S WARRANT

 

FOR THE PURCHASE OF [*] ORDINARY SHARES

 

OF

 

MAGIC EMPIRE GLOBAL LIMITED

 

1. Purchase
Warrant. THIS CERTIFIES THAT, pursuant to that certain Underwriting Agreement by and between Magic Empire Global Limited, a British
Virgin Islands company limited by shares (the “Company”), on one hand, and Network 1 Financial Securities, Inc., on
the other hand, dated August 4, 2022 (the “Underwriting Agreement”), [*], (the “Holder”), as registered
owner of this Purchase Warrant, is entitled, at any time or from time to time from August 9, 2022 (the “Exercise Date”),
and at or before 5:00 p.m., Eastern time, on August 8, 2027, (the “Expiration Date”), but not thereafter, to subscribe
for, purchase and receive, in whole or in part, [*] ordinary shares of the Company, par value $0.0001 per share (the “Shares”),
subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions
are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance
with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate
this Purchase Warrant. This Purchase Warrant is initially exercisable at $6.00 per Share (150% of the price of the ordinary shares (“Ordinary
Shares”) sold in the offering pursuant to the registration statement of the Company’s securities (File No. 333-264575)(the
“Offering”)); provided, however, that upon the occurrence of any of the events specified in Section
6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Ordinary Share and the number of Ordinary
Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean
the initial exercise price as set forth above or the adjusted exercise price as a result of the events set forth in Section 6 below, depending
on the context. Capitalized terms not defined herein shall have the meaning ascribed to them in the Underwriting Agreement. 

 

2. Exercise.

 

2.1 Exercise
Notice. In order to exercise this Purchase Warrant, the exercise notice attached hereto as Exhibit A must be
duly executed and completed and delivered to the Company, together with this Purchase Warrant and payment of the Exercise Price for
the Ordinary Shares being purchased payable in cash by wire transfer of immediately available funds to an account designated by the
Company or by certified check. If the subscription rights represented hereby shall not be exercised at or before 5:00 p.m., Eastern
time, on the Expiration Date, this Purchase Warrant shall become and be void without further force or effect, and all rights
represented hereby shall cease and expire.

 

 

		1	Five years from the commencement of sales of the public offering.

 

     

     

    

 

2.2 Cashless
Exercise. In lieu of exercising this Purchase Warrant by payment of cash pursuant to Section 2.1 above, Holder may
elect to receive the number of Ordinary Shares equal to the value of this Purchase Warrant (or the portion thereof being exercised), by
surrender of this Purchase Warrant to the Company, together with the exercise notice attached hereto, in which event the Company shall
issue to Holder, Shares in accordance with the following formula:

 

	X	=	Y(A-B)	 	 
	A	 	 
	 	 	 	 
	Where,	X	=	The number of Ordinary Shares to be issued to Holder;
	 	Y	=	The number of Ordinary Shares for which the Purchase Warrant is being exercised;
	 	A	=	The fair market value of one Ordinary Share; and
	 	B	=	The Exercise Price.

 

For purposes of this Section
2.2, the “fair market value” of an Ordinary Share is defined as follows:

 

		(i)	if the Ordinary Shares are traded on a national securities exchange, the value shall be deemed to be the
closing price on the day immediately prior to the exercise notice being submitted in connection with the exercise of the Purchase Warrant;
or

 

		(ii)	if the Ordinary Shares are actively traded over-the-counter, the value shall be deemed to be the closing
price of the Ordinary Shares on the day immediately prior to the exercise notice being submitted in connection with the exercise of the
Purchase Warrant; or

 

		(iii)	if there is no market for the Ordinary Shares, the value shall be the fair market value thereof, as determined
in good faith by the Company’s Board of Directors.

 

2.3 Mechanics
of Exercise. The Company shall cause the Shares purchased hereunder to be transmitted by the Transfer Agent to the Holder by
crediting the account of the Holder’s or its designee’s balance account with The Depository Trust Company through its Deposit
or Withdrawal at Custodian systems (“DWAC”) or Direct Registration System (“DRS”), at the Holder’s discretion,
if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance
of the Warrant Shares or resale of the Warrant Shares by the Holder or (B) the Purchase Warrant are eligible for resale by the Holder
without volume or manner-of-sale limitations pursuant to Rule 144 (assuming cashless exercise of the Warrants), and otherwise by physical
delivery of a certificate, registered in the Company’s share register in the name of the Holder or its designee, for the number
of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise
by three (3) Trading Days after the delivery to the Company of the Notice of Exercise. Upon delivery of the Notice of Exercise, the Holder
shall be deemed for all corporate purposes to have become the holder of record of the Shares purchased hereunder with respect to which
this Warrant has been exercised, irrespective of the date of delivery of the Shares, provided that payment of the aggregate Exercise Price
(other than in the case of a cashless exercise) is received. The Company
agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable.

 

2.4 Legend.
Each certificate for the securities purchased under this Purchase Warrant shall bear the following legends unless such securities have
been registered under the Securities Act of 1933, as amended (the “Act”), or are exempt from registration under the
Act:

 

(i) “THE SECURITIES
REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO A LOCK-UP PERIOD THROUGH AND INCLUDING ONE HUNDRED EIGHTY (180) DAYS FROM THE
COMMENCEMENT OF THE COMPANY’S FIRST DAY OF TRADING PURSUANT TO THE REGISTRATION STATEMENT OF THE COMPANY’S SECURITIES
(FILE NO. 333-264575) AND MAY NOT BE SOLD, TRANSFERRED, ASSIGNED, PLEDGEDOR HYPOTHECATED, OR CAUSED TO BE THE SUBJECT OF ANY
HEDGING, SHORT SALE, DERIVATIVE, PUT OR CALL TRANSACTION THAT WOULD RESULT IN THE EFFECTIVE ECONOMIC DISPOSITION OF THE SECURITIES
HEREUNDER, EXCEPT THAT SUCH LOCK-UP RESTRICTION DOES NOT PROHIBIT (I) TRANSFERS TO ANY UNDERWRITER OR SELECTED DEALER PARTICIPATING
IN THE OFFERING AND ITS OFFICERS OR PARTNERS, ITS REGISTERED PERSONS OR AFFILIATES, IF ALL TRANSFERRED SECURITIES REMAIN SUBJECT TO
THE LOCK-UP RESTRICTION FOR THE REMAINDER OF THE 180-DAY LOCK-UP PERIOD, (II) EXERCISE OR CONVERSION OF THE PURCHASE WARRANT, IF ALL
SECURITIES RECEIVED REMAIN SUBJECT TO THE LOCK-UP RESTRICTION FOR THE REMAINDER OF THE 180-DAY LOCK-UP PERIOD, OR (III) TRANSFERS OR
SALE OF THE PURCHASE WARRANT OR SECURITIES THEREUNDER BACK TO THE COMPANY, IN A TRANSACTION EXEMPT FROM REGISTRATION WITH THE
SECURITIES AND EXCHANGE COMMISSION, AS PROVIDED FOR IN FINRA RULE 5110(E)(2).”

 

    2

     

    

 

(ii) Any legend required by the securities
laws of any state to the extent such laws are applicable to the Shares represented by a certificate, instrument, or book entry so legended.

  

3. Transfer.

 

3.1 General
Restrictions. The registered Holder of this Purchase Warrant agrees by his, her or its acceptance hereof, that such Holder will not,
for a period through and including one hundred eighty (180) days from the commencement of sales of the Offering(the “Effective
Date”), sell, transfer, assign, pledge or hypothecate this Purchase Warrant , or cause this Purchase Warrant or the securities
issuable hereunder to be the subject of any hedging, short sale, derivative, put or call transaction that would result in the effective
economic disposition of this Purchase Warrant or the securities hereunder, in accordance with FINRA Conduct Rule 5110(e)(1). The foregoing
restriction does not prohibit (i) transfer of the Underwriter’s Warrant or the securities thereunder to any underwriter or selected
dealer participating in the Offering and its officers or partners, its registered persons or affiliates, if all transferred securities
remain subject to the lock-up restriction for the remainder of the 180-day lock-up period, (ii) exercise or conversion of the Underwriter’s
Warrant, if all securities received remain subject to the lock-up restriction for the remainder of the 180-day lock-up period, and (iii)
transfer or sale of the Underwriter’s Warrant or securities thereunder back to the Company in a transaction exempt from registration
with the Commission, as provided for in FINRA Rule 5110(e)(2). The registered Holder of this Purchase Warrant will have the option to
exercise their warrants at any time, provided that such shares are not transferred during the lock-up period; the 180-day lock period
will remain on these underlying shares. The Purchase Warrant may not be sold, transferred, assigned, pledged or hypothecated, or be the
subject of any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of the
securities by any person for a period of 180 days beginning on the date of the commencement of sales of the offering in accordance with
FINRA Rule 5110(e)(1), except that (i) they may be transferred, in whole or in part, to any member participating in the offering and its
officers or partners, its registered persons or affiliates, if all transferred securities remain subject to the lock-up restriction for
the remainder of the 180-day lock-up period, (ii) they may be exercised or converted, in whole or in part, if all securities received
remain subject to the lock-up restriction for the for the remainder of the 180-day lock-up period, (iii) they may be transferred back
to the issuer in a transaction exempt from registration with the SEC, or other exceptions as provided under FIRNA Rule 5110(e)(2).On and
after the 180-day lock-up period, transfers to others may be made subject to compliance with or exemptions from applicable securities
laws. In order to make any permitted assignment, the Holder must deliver to the Company the assignment form attached hereto as Exhibit
B duly executed and completed, together with this Purchase Warrant and payment of all transfer taxes, if any, payable in connection
therewith. The Company shall within five (5) Business Days transfer this Purchase Warrant on the books of the Company and shall execute
and deliver a new Purchase Warrant or Purchase Warrants of like tenor to the appropriate assignee(s) expressly evidencing the right to
purchase the aggregate number of Ordinary Shares purchasable hereunder or such portion of such number as shall be contemplated by any
such assignment.

 

    3

     

    

 

3.2 Restrictions
Imposed by the Act. The securities evidenced by this Purchase Warrant shall not be transferred unless and until: (i) the Company has
received the opinion of counsel for the Company that the securities may be transferred pursuant to an exemption from registration under
the Act and applicable state securities laws, the availability of which is established to the reasonable satisfaction of the Company,
(ii) a registration statement or a post-effective amendment to the Registration Statement relating to the offer and sale of such securities
that has been declared effective by the U.S. Securities and Exchange Commission (the “Commission”) and includes a current
prospectus or (iii) a registration statement, relating to the offer and sale of such securities has been filed and declared effective
by the Commission and compliance with applicable state securities law has been established.

 

4. Registration
Rights.

 

4.1 Demand Registration

 

4.1.1 Grant
of Right. The Company, upon written demand (a “Demand Notice”) of the Holder(s) of at least 51% of the Warrants and/or the
underlying Warrant Shares (“Majority Holders”), agrees to register, on one occasion, all or any portion of the Warrant Shares
underlying the Warrants (collectively, the “Registrable Securities”). On such occasion, the Company will file a registration
statement with the Commission covering the Registrable Securities within sixty (60) days after receipt of a Demand Notice and use its
reasonable best efforts to have the registration statement declared effective promptly thereafter, subject to compliance with review by
the Commission; provided, however, that the Company shall not be required to comply with a Demand Notice if the Company has filed a registration
statement with respect to which the Holder is entitled to piggyback registration rights pursuant to Section 4.2 hereof and either: (i)
the Holder has elected to participate in the offering covered by such registration statement or (ii) if such registration statement relates
to an underwritten primary offering of securities of the Company, until the offering covered by such registration statement has been withdrawn
or until thirty (30) days after such offering is consummated. The demand for registration may be made at any time beginning on the Exercise
Date and expiring on the fifth anniversary of the Effective Date. The Company covenants and agrees to give written notice of its receipt
of any Demand Notice by any Holder(s) to all other registered Holders of the Warrants and/or the Registrable Securities within ten (10)
days after the date of the receipt of any such Demand Notice.

 

4.1.2 Terms.
Except as otherwise stated in this subsection, the Company shall bear all fees and expenses attendant to the registration of the Registrable
Securities pursuant to Section 4.1.1, but the Holders shall pay any and all underwriting commissions and the expenses of any legal counsel
selected by the Holders to represent them in connection with the sale of the Registrable Securities. The Company agrees to use its reasonable
best efforts to cause the filing required herein to become effective promptly and to qualify or register the Registrable Securities in
such States as are reasonably requested by the Holder(s); provided, however, that in no event shall the Company be required to register
the Registrable Securities in a State in which such registration would cause: (i) the Company to be obligated to register or license to
do business in such State or submit to general service of process in such State, or (ii) the principal stockholders of the Company to
be obligated to escrow their shares of capital stock of the Company. The Company shall cause any registration statement filed pursuant
to the demand right granted under Section 4.1.1 to remain effective for a period of at least twelve (12) consecutive months after the
date that the Holders of the Registrable Securities covered by such registration statement are first given the opportunity to sell all
of such securities. The Holders shall only use the prospectuses provided by the Company to sell the Warrant Shares covered by such registration
statement, and will immediately cease to use any prospectus furnished by the Company if the Company advises the Holder that such prospectus
may no longer be used due to a material misstatement or omission. Notwithstanding the provisions of this Section 4.1.2, the Holder shall
be entitled to a demand registration under this Section 4.1.2 on two (2) occasions and such demand registration right shall terminate
on the fifth anniversary of the date of the Underwriting Agreement in accordance with FINRA Rule 5110(g)(8)(C). The second time the Majority
Holders exercise the demand registration right, the Holders shall bear all fees and expenses attendant to the registration of the Registrable
Securities.

 

    4

     

    

 

4.2 “Piggy-Back”
Registration.

 

4.2.1 Grant
of Right. In addition to the demand right of registration described in Section 4.1 hereof, the Holder shall have unlimited right, for
a period of no more than five (5) years from the Exercise Date in accordance with FINRA Rule 5110(g)(8)(D), to include the Registrable
Securities as part of any other registration of securities filed by the Company (other than in connection with a transaction contemplated
by Rule 145(a) promulgated under the Securities Act or pursuant to Form S-8 or any equivalent form); provided, however, that if, solely
in connection with any primary underwritten public offering for the account of the Company, the managing underwriter(s) thereof shall,
in its reasonable discretion, impose a limitation on the number of Shares which may be included in the Registration Statement because,
in such underwriter(s)’ judgment, marketing or other factors dictate such limitation is necessary to facilitate public distribution,
then the Company shall be obligated to include in such Registration Statement only such limited portion of the Registrable Securities
with respect to which the Holder requested inclusion hereunder as the underwriter shall reasonably permit. Any exclusion of Registrable
Securities shall be made pro rata among the Holders seeking to include Registrable Securities in proportion to the number of Registrable
Securities sought to be included by such Holders; provided, however, that the Company shall not exclude any Registrable Securities unless
the Company has first excluded all outstanding securities, the holders of which are not entitled to inclusion of such securities in such
Registration Statement or are not entitled to pro rata inclusion with the Registrable Securities.

 

5. New
Purchase Warrants to be Issued.

 

5.1 Partial
Exercise or Transfer. Subject to the restrictions in Section 3 hereof, this Purchase Warrant may be exercised or
assigned in whole or in part. In the event of the exercise or assignment hereof in part only, upon surrender of this Purchase Warrant
for cancellation, together with the duly executed exercise or assignment form and funds sufficient to pay any Exercise Price and/or transfer
tax if exercised pursuant to Section 2.1 hereof, the Company shall cause to be delivered to the Holder without charge
a new Purchase Warrant of like tenor to this Purchase Warrant in the name of the Holder evidencing the right of the Holder to purchase
the number of Ordinary Shares purchasable hereunder as to which this Purchase Warrant has not been exercised or assigned.

 

5.2 Lost
Certificate. Upon receipt by the Company of evidence satisfactory to it of the loss, theft, destruction or mutilation of this Purchase
Warrant and of reasonably satisfactory indemnification or the posting of a bond, the Company shall execute and deliver a new Purchase
Warrant of like tenor and date. Any such new Purchase Warrant executed and delivered as a result of such loss, theft, mutilation or destruction
shall constitute a substitute contractual obligation on the part of the Company.

 

6. Adjustments.

 

6.1 Adjustments
to Exercise Price and Number of Ordinary Shares. The Exercise Price and the number of Ordinary Shares underlying this Purchase Warrant
shall be subject to adjustment from time to time as hereinafter set forth:

 

6.1.1 Share
Dividends; Split Ups. If, after the date hereof, and subject to the provisions of Section 6.3 below, the number of
outstanding Ordinary Shares is increased by a stock dividend payable in Ordinary Shares or by a split up of Ordinary Shares or other similar
event, then, on the effective day thereof, the number of Ordinary Shares purchasable hereunder shall be increased in proportion to such
increase in outstanding Ordinary Shares, and the Exercise Price shall be proportionately decreased.

 

6.1.2 Aggregation
of Ordinary Shares. If, after the date hereof, and subject to the provisions of Section 6.3 below, the number of
outstanding Ordinary Shares is decreased by a consolidation, combination or reclassification of Ordinary Shares or other similar event,
then, on the effective date thereof, the number of Ordinary Shares purchasable hereunder shall be decreased in proportion to such decrease
in outstanding shares, and the Exercise Price shall be proportionately increased.

  

6.1.3 Replacement
of Ordinary Shares upon Reorganization, etc. In case of any reclassification or reorganization of the outstanding Ordinary
Shares other than a change covered by Section 6.1.1 or Section 6.1.2 hereof or that solely affects
the par value of such Ordinary Shares, or in the case of any share reconstruction or amalgamation or consolidation of the Company
with or into another corporation (other than a consolidation or share reconstruction or amalgamation in which the Company is the
continuing corporation and that does not result in any reclassification or reorganization of the outstanding Ordinary Shares), or in
the case of any sale or conveyance to another corporation or entity of the property of the Company as an entirety or substantially
as an entirety in connection with which the Company is dissolved, the Holder of this Purchase Warrant shall have the right
thereafter (until the expiration of the right of exercise of this Purchase Warrant) to receive upon the exercise hereof, for the
same aggregate Exercise Price payable hereunder immediately prior to such event, the kind and amount of ordinary shares or other
securities or property (including cash) receivable upon such reclassification, reorganization, share reconstruction or amalgamation,
or consolidation, or upon a dissolution following any such sale or transfer, by a Holder of the number of Ordinary Shares of the
Company obtainable upon exercise of this Purchase Warrant immediately prior to such event; and if any reclassification also results
in a change in Ordinary Shares covered by Section 6.1.1 or Section 6.1.2, then such adjustment shall be
made pursuant to Section 6.1.1, Section 6.1.2 and this Section 6.1.3. The provisions of
this Section 6.1.3 shall similarly apply to successive reclassifications, reorganizations, share reconstructions or
amalgamations, or consolidations, sales or other transfers.

 

    5

     

    

 

6.1.4
 Fundamental Transaction. If, at any time while this Purchase Warrant is
outstanding, the Company enters into the following transactions with another Person or group of Persons whereby such other Person or
group acquires more than 50% of the outstanding Ordinary Shares (not including any Ordinary Shares held by the other Person or other
Persons making or party to, or associated or affiliated with, the other Persons making or party to such stock or share purchase
agreement or other business combination): (i) the Company, directly or indirectly, in one or more related transactions effects any
merger or consolidation of the Company with or into another Person, (ii) the Company, directly or indirectly, effects any sale,
lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series
of related transactions, (iii) any direct or indirect purchase offer, tender offer or exchange offer (whether by the Company or
another Person) is completed pursuant to which holders of Ordinary Shares are permitted to sell, tender or exchange their shares for
other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Ordinary Shares, (iv) the
Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or
recapitalization of the Ordinary Shares or any compulsory share exchange pursuant to which the Ordinary Shares is effectively
converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more
related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a
reorganization, recapitalization, spinoff or scheme of arrangement) with another Person or group of Persons (each a
“Fundamental Transaction”), then, upon any subsequent exercise of this Purchase Warrant, the Holder shall have
the right to receive, for each Purchase Warrant Share that would have been issuable upon such exercise immediately prior to the
occurrence of such Fundamental Transaction, the number Ordinary Shares of the successor or acquiring corporation or of the Company,
if it is the surviving corporation, and any additional or alternative consideration (the “Alternative
Consideration”) receivable as a result of such Fundamental Transaction by a holder of the number of Ordinary Shares for
which this Purchase Warrant is exercisable immediately prior to such Fundamental Transaction. For purposes of any such exercise, the
determination of the Exercise Price shall be appropriately adjusted to apply to such Alternative Consideration based on the amount
of Alternative Consideration issuable in respect of one Ordinary Share in such Fundamental Transaction, and the Company shall
apportion the Exercise Price among the Alternative Consideration in a reasonable manner reflecting the relative value of any
different components of the Alternative Consideration. If holders of Ordinary Shares are given any choice as to the securities, cash
or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternative
Consideration it receives upon any exercise of this Purchase Warrant following such Fundamental Transaction. The Company shall cause
any successor entity in a Fundamental Transaction in which the Company is not the survivor (the “Successor
Entity”) to assume in writing all of the obligations of the Company under this Purchase Warrant, and to deliver to the
Holder in exchange for this Purchase Warrant a security of the Successor Entity evidenced by a written instrument substantially
similar in form and substance to this Purchase Warrant which is exercisable for a corresponding number of shares of capital stock of
such Successor Entity (or its parent entity) equivalent to the Ordinary Shares acquirable and receivable upon exercise of this
Purchase Warrant prior to such Fundamental Transaction, and with an exercise price which applies the Exercise Price hereunder to
such shares of capital stock (but taking into account the relative value of the Ordinary Shares pursuant to such Fundamental
Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for
the purpose of protecting the economic value of this Purchase Warrant immediately prior to the consummation of such Fundamental
Transaction). Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for
(so that from and after the date of such Fundamental Transaction, the provisions of this Purchase Warrant and the other Transaction
Documents referring to the “Company” shall refer instead to the Successor Entity), and may exercise every right and
power of, the Company and shall assume all of the obligations of the Company, under this Purchase Warrant and the other Transaction
Documents with the same effect as if such Successor Entity had been named as the Company herein.

 

    6

     

    

 

6.1.5  Changes in Form
of Purchase Warrant. This form of Purchase Warrant need not be changed because of any change pursuant to this Section 6.1,
and Purchase Warrants issued after such change may state the same Exercise Price and the same number of Ordinary Shares as are stated
in the Purchase Warrants initially issued pursuant to this Agreement. The acceptance by any Holder of the issuance of new Purchase Warrants
reflecting a required or permissive change shall not be deemed to waive any rights to an adjustment occurring after the date hereof or
the computation thereof.

 

6.2 Substitute
Purchase Warrant. In case of any consolidation of the Company with, or share reconstruction or amalgamation of the Company with or
into, another corporation (other than a consolidation or share reconstruction or amalgamation which does not result in any reclassification
or change of the outstanding Ordinary Shares), the corporation formed by such consolidation or share reconstruction or amalgamation shall
execute and deliver to the Holder a supplemental Purchase Warrant providing that the holder of each Purchase Warrant then outstanding
or to be outstanding shall have the right thereafter (until the stated expiration of such Purchase Warrant) to receive, upon exercise
of such Purchase Warrant, the kind and amount of Ordinary Shares and other securities and property receivable upon such consolidation
or share reconstruction or amalgamation, by a holder of the number of Ordinary Shares of the Company for which such Purchase Warrant might
have been exercised immediately prior to such consolidation, share reconstruction or amalgamation, sale or transfer. Such supplemental
Purchase Warrant shall provide for adjustments which shall be identical to the adjustments provided for in this Section 6.
The above provision of this Section 6 shall similarly apply to successive consolidations or share reconstructions or
amalgamations. 

 

6.3 Elimination
of Fractional Interests. The Company shall not be required to issue certificates representing fractions of Ordinary Shares upon the
exercise of the Purchase Warrant, nor shall it be required to issue scrip or pay cash in lieu of any fractional interests, it being the
intent of the parties that all fractional interests shall be eliminated by rounding any fraction up or down, as the case may be, to the
nearest whole number of Ordinary Shares or other securities, properties or rights.

 

7. Reservation
and Listing. The Company shall at all times reserve and keep available out of its authorized Ordinary Shares, solely for the purpose
of issuance upon exercise of this Purchase Warrant, such number of Ordinary Shares or other securities, properties or rights as shall
be issuable upon the exercise thereof. The Company covenants and agrees that, upon exercise of this Purchase Warrant and payment of the
Exercise Price therefor, in accordance with the terms hereby, all Ordinary Shares and other securities issuable upon such exercise shall
be duly and validly issued, fully paid and non-assessable and not subject to preemptive rights of any shareholder. The Company further
covenants and agrees that upon exercise of this Purchase Warrant and payment of the exercise price therefor, all Ordinary Shares and other
securities issuable upon such exercise shall be duly and validly issued, fully paid and non-assessable and not subject to preemptive rights
of any shareholder. As long as this Purchase Warrant shall be outstanding, the Company shall use its commercially reasonable efforts to
cause all Ordinary Shares issuable upon exercise of this Purchase Warrant to be listed (subject to official notice of issuance) on all
national securities exchanges (or, if applicable, on the OTCQB Market or any successor quotation system) on which the Ordinary Shares
issued to the public in the Offering may then be listed and/or quoted (if at all).

 

8. Certain
Notice Requirements.

 

8.1 Holder’s
Right to Receive Notice. Nothing herein shall be construed as conferring upon the Holders the right to vote or consent or to receive
notice as a shareholder for the election of directors or any other matter, or as having any rights whatsoever as a shareholder of the
Company. If, however, at any time prior to the expiration of the Purchase Warrants and their exercise, any of the events described in Section
8.2 shall occur, then, in one or more of said events, the Company shall give written notice of such event at least fifteen days
prior to the date fixed as a record date or the date of closing the transfer books (the “Notice Date”) for the determination
of the shareholders entitled to such dividend, distribution, conversion or exchange of securities or subscription rights, or entitled
to vote on such proposed dissolution, liquidation, winding up or sale. Such notice shall specify such record date or the date of the
closing of the transfer books, as the case may be. Notwithstanding the foregoing, the Company shall deliver to each Holder a copy of
each notice given to the other shareholders of the Company at the same time and in the same manner that such notice is given to the shareholders.

 

    7

     

    

 

8.2 Events
Requiring Notice. The Company shall be required to give the notice described in this Section 8 upon one or more of
the following events: (i) if the Company shall take a record of the holders of its Ordinary Shares for the purpose of entitling them to
receive a dividend or distribution payable otherwise than in cash, or a cash dividend or distribution payable otherwise than out of retained
earnings, as indicated by the accounting treatment of such dividend or distribution on the books of the Company, (ii) the Company shall
offer to all the holders of its Ordinary Shares any additional shares of capital stock of the Company or securities convertible into or
exchangeable for shares of capital stock of the Company, or any option, right or warrant to subscribe therefor, or (iii) a dissolution,
liquidation or winding up of the Company (other than in connection with a consolidation or share reconstruction or amalgamation) or a
sale of all or substantially all of its property, assets and business shall be proposed. 

 

8.3 Notice
of Change in Exercise Price. The Company shall, promptly after an event requiring a change in the Exercise Price pursuant to Section
6 hereof, send notice to the Holders of such event and change (“Price Notice”). The Price Notice shall describe
the event causing the change and the method of calculating same and shall be certified as being true and accurate by the Company’s
Chief Financial Officer.

 

8.4 Transmittal
of Notices. All notices, requests, consents and other communications under this Purchase Warrant shall be in writing and shall be
deemed to have been duly made if made in accordance with the notice provisions of the Underwriting Agreement to the addresses and contact
information set forth below:

 

If to the Holder, then to:

 

Network 1 Financial Securities, Inc.

The Galleria, 2 Bridge Ave., Suite 241

Red Bank, NJ 07701

Attn: Adam Pasholk, Managing Director

Email: AdamPasholk@netw1.com

Phone No.: (732) 758-9001

Fax No.: (732)758-6671

 

With a copy (which shall
not constitute notice) to:

 

Ortoli Rosenstadt LLP

366 Madison Avenue, 3rd Floor

New York, NY 10017

Attn: William S. Rosenstadt, Esq.

Attn: Mengyi “Jason” Ye, Esq.

		Email:	wsr@orllp.legal

jye@orllp.legal

Fax No.: (212) 826-9307

 

If to the Company:

 

Magic Empire Global Limited

3/F, 8 Wyndham Street

Central, Hong Kong

Attn: Gilbert Chan, Managing Director / Johnson Chen,
Managing Director

Email: gilbert@giraffecap.com / johnson@giraffecap.com

Phone: (852) 3577 8771

 

    8

     

    

 

With a copy (which shall not constitute notice)
to:

 

Loeb & Loeb LLP

2206-19 Jardine House

1 Connaught Place, Central

Hong Kong SAR

Attn: Lawrence S. Venick

Email: lvenick@loeb.com

Fax No.: 852-3923-1100

 

9. Miscellaneous.

 

9.1 Amendments.
The Company and the underwriter may from time to time supplement or amend this Purchase Warrant without the approval of any of the Holders
in order to cure any ambiguity, to correct or supplement any provision contained herein that may be defective or inconsistent with any
other provisions herein, or to make any other provisions in regard to matters or questions arising hereunder that the Company and the
underwriter may deem necessary or desirable and that the Company and the underwriter deem shall not adversely affect the interest of the
Holders. All other modifications or amendments shall require the written consent of and be signed by the party against whom enforcement
of the modification or amendment is sought.

 

9.2 Headings.
The headings contained herein are for the sole purpose of convenience of reference, and shall not in any way limit or affect the meaning
or interpretation of any of the terms or provisions of this Purchase Warrant.

 

9.3. Entire
Agreement. This Purchase Warrant (together with the other agreements and documents being delivered pursuant to or in connection with
this Purchase Warrant) constitutes the entire agreement of the parties hereto with respect to the subject matter hereof, and supersedes
all prior agreements and understandings of the parties, oral and written, with respect to the subject matter hereof.

 

9.4 Binding
Effect. This Purchase Warrant shall inure solely to the benefit of and shall be binding upon, the Holder and the Company and their
permitted assignees, respective successors, legal representative and assigns, and no other person shall have or be construed to have any
legal or equitable right, remedy or claim under or in respect of or by virtue of this Purchase Warrant or any provisions herein contained.

 

9.5 Governing
Law; Submission to Jurisdiction; Trial by Jury. This Purchase Warrant shall be governed by and construed and enforced in accordance
with the internal laws of the State of New York, without giving effect to conflict of laws principles thereof. The Company hereby agrees
that any action, proceeding or claim against it arising out of, or relating in any way to this Purchase Warrant shall be brought and enforced
in the New York Supreme Court, County of New York, or in the United States District Court for the Southern District of New York, and irrevocably
submits to such jurisdiction, which jurisdiction shall be exclusive. The Company hereby waives any objection to such exclusive jurisdiction
and that such courts represent an inconvenient forum. Any process or summons to be served upon the Company may be served by transmitting
a copy thereof by registered or certified mail, return receipt requested, postage prepaid, addressed to it at the address set forth in Section
8 hereof. Such mailing shall be deemed personal service and shall be legal and binding upon the Company in any action, proceeding
or claim. The Company and the Holder agree that the prevailing party(ies) in any such action shall be entitled to recover from the other
party(ies) all of its reasonable attorneys’ fees and expenses relating to such action or proceeding and/or incurred in connection
with the preparation therefor. The Company (on its behalf and, to the extent permitted by applicable law, on behalf of its stockholders
and affiliates) and the Holder hereby irrevocably waive, to the fullest extent permitted by applicable law, any and all right to trial
by jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated hereby.

 

9.6 Waiver,
etc. The failure of the Company or the Holder to at any time enforce any of the provisions of this Purchase Warrant shall not be deemed
or construed to be a waiver of any such provision, nor to in any way affect the validity of this Purchase Warrant or any provision hereof
or the right of the Company or any Holder to thereafter enforce each and every provision of this Purchase Warrant. No waiver of any breach,
non-compliance or non-fulfillment of any of the provisions of this Purchase Warrant shall be effective unless set forth in a written instrument
executed by the party or parties against whom or which enforcement of such waiver is sought; and no waiver of any such breach, non-compliance
or non-fulfillment shall be construed or deemed to be a waiver of any other or subsequent breach, non-compliance or non-fulfillment.

 

    9

     

    

 

9.7 Exchange
Agreement. As a condition of the Holder’s receipt and acceptance of this Purchase Warrant, Holder agrees that, at any time prior
to the complete exercise of this Purchase Warrant by Holder, if the Company and the underwriter enter into an agreement (“Exchange
Agreement”) pursuant to which they agree that all outstanding Purchase Warrants will be exchanged for securities or cash or
a combination of both, then Holder shall agree to such exchange and become a party to the Exchange Agreement.

 

9.8 Execution
in Counterparts. This Purchase Warrant may be executed in one or more counterparts, and by the different parties hereto in separate
counterparts, each of which shall be deemed to be an original, but all of which taken together shall constitute one and the same agreement,
and shall become effective when one or more counterparts has been signed by each of the parties hereto and delivered to each of the other
parties hereto. Such counterparts may be delivered by facsimile transmission or other electronic transmission.

 

9.9 Holder
Not Deemed a Shareholder. Except as otherwise specifically provided herein, the Holder, solely in its capacity as a holder of this
Purchase Warrant, shall not be entitled to vote or receive dividends or be deemed the holder of share capital of the Company for any purpose,
nor shall anything contained in this Purchase Warrant be construed to confer upon the Holder, solely in its capacity as the Holder of
this Purchase Warrant, any of the rights of a shareholder of the Company or any right to vote, give or withhold consent to any corporate
action (whether any reorganization, issue of share, reclassification of share, consolidation, merger, conveyance or otherwise), receive
notice of meetings, receive dividends or subscription rights, or otherwise, prior to the issuance to the Holder of the Shares which it
is then entitled to receive upon the due exercise of this Purchase Warrant. In addition, nothing contained in this Purchase Warrant shall
be construed as imposing any liabilities on the Holder to purchase any securities (upon exercise of this Purchase Warrant or otherwise)
or as a shareholder of the Company, whether such liabilities are asserted by the Company or by creditors of the Company.

 

9.10 Restrictions.
The Holder acknowledges that the Shares acquired upon the exercise of this Purchase Warrant, if not registered, and the Holder does not
utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.

 

9.10 Severability.
Wherever possible, each provision of this Purchase Warrant shall be interpreted in such manner as to be effective and valid under applicable
law, but if any provision of this Purchase Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective
to the extent of such prohibition or invalidity, without invalidating the remainder of such provision or the remaining provisions of this
Purchase Warrant.

 

[Signature Page Follows]

 

    10

     

    

 

IN WITNESS WHEREOF, the Company has caused
this Purchase Warrant to be signed by its duly authorized officer as of the 9th day of August, 2022.

 

	 	MAGIC EMPIRE GLOBAL LIMITED
	 	 	 
	 	By: 	    
	 	 	Name: 
	 	 	Title: 

 

    11

     

    

 

EXHIBIT A

Exercise Notice

 

Form to be used to exercise Purchase Warrant:

 

Date: __________, 20___

 

The undersigned hereby elects
irrevocably to exercise the Purchase Warrant for ______ Ordinary Shares of Magic Empire Global Limited, a British Virgin Islands company
(the “Company”) and hereby makes payment of $____ (at the rate of $____ per Ordinary Share) in payment of the Exercise
Price pursuant thereto. Please issue the Ordinary Shares as to which this Purchase Warrant is exercised in accordance with the instructions
given below and, if applicable, a new Purchase Warrant representing the number of Ordinary Shares for which this Purchase Warrant has
not been exercised.

 

or

 

The undersigned hereby elects
irrevocably to convert its right to purchase ___ Ordinary Shares under the Purchase Warrant for ______ Ordinary Shares, as determined
in accordance with the following formula:

 

	 	 X	=	Y(A-B)	 
	 	A	 
	Where,	X	=	The number of Ordinary Shares to be issued to Holder;
	 	Y	=	The number of Ordinary Shares for which the Purchase Warrant is being exercised;
	 	A	=	The fair market value of one Ordinary Share which is equal to $_____; and
	 	B	=	The Exercise Price which is equal to $______ per Ordinary Share

 

The undersigned agrees and
acknowledges that the calculation set forth above is subject to confirmation by the Company and any disagreement with respect to the calculation
shall be resolved by the Company in its sole discretion.

 

Please issue the Ordinary
Shares as to which this Purchase Warrant is exercised in accordance with the instructions given below and, if applicable, a new Purchase
Warrant representing the number of Ordinary Shares for which this Purchase Warrant has not been converted.

 

Signature

 

Signature Guaranteed

 

INSTRUCTIONS FOR REGISTRATION OF SECURITIES

 

Name:

(Print in Block Letters)

Address:

 

NOTICE: The signature to this
form must correspond with the name as written upon the face of the Purchase Warrant without alteration or enlargement or any change whatsoever,
and must be guaranteed by a bank, other than a savings bank, or by a trust company or by a firm having membership on a registered national
securities exchange.

 

    12

     

    

 

EXHIBIT B

Assignment Notice

 

Form to be used to assign Purchase Warrant:

 

ASSIGNMENT

 

(To be executed by the registered Holder to effect a transfer of the
within Purchase Warrant):

 

FOR VALUE RECEIVED,                                                     does
hereby sell, assign and transfer unto the right to purchase   ordinary shares of Magic Empire Global Limited, a British
Virgin Islands company (the “Company”), evidenced by the Purchase Warrant and does hereby authorize the Company to
transfer such right on the books of the Company.

 

Dated:            ,
20

 

Signature

 

Signature Guaranteed

 

NOTICE: The signature to this
form must correspond with the name as written upon the face of the within Purchase Warrant without alteration or enlargement or any change
whatsoever, and must be guaranteed by a bank, other than a savings bank, or by a trust company or by a firm having membership on a registered
national securities exchange.

 

 

13

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00347-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00347-of-00352.parquet"}]]